ArticleEBioMedicine2018
CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis.
Article in EBioMedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Dietary Lipid Quantity and Quality Modulate the Postprandial Metabolomic Profile in Patients with Metabolic Syndrome.Nutrients · 2024Trial
- Trial
- Furan fatty acids reprogram hepatic lipid metabolism via acyl-CoA conjugates in obesity.Science advances · 2026Article
- A multi-functional oral small molecule targeting energy and lipid metabolism to treat obesity and related metabolic disorders.Science advances · 2026Article
- A scoping review on the possible immunometabolic properties of the furan fatty acid metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid.The American journal of clinical nutrition · 2025Article
- The emerging significance of furan fatty acids in food, nutrition, and potential therapeutic use.Food chemistry · 2025Review
- Serum and urine metabolite correlates of vitamin D supplementation in the Atherosclerosis Risk in Communities (ARIC) study.Clinical nutrition ESPEN · 2025Article
- Machine Learning Metabolomics Profiling of Dietary Interventions from a Six-Week Randomised Trial.Metabolites · 2024Article
- Association of Plasma Selenium and Its Untargeted Metabolomic Profiling with Cervical Cancer Prognosis.Biological trace element research · 2023Observational
- Metabolomics of Dietary Intake of Total, Animal, and Plant Protein: Results from the Atherosclerosis Risk in Communities (ARIC) Study.Current developments in nutrition · 2023Article
- The gut-derived metabolites as mediators of the effect of healthy nutrition on the brain.Frontiers in nutrition · 2023Review
- Metabolomics Profiling of Age-Associated Metabolites in Malay Population.Oxidative medicine and cellular longevity · 2023Article
- The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study.The American journal of clinical nutrition · 2022Article
- Metabolomics of Synovial Fluid and Infrapatellar Fat Pad in Patients with Osteoarthritis or Rheumatoid Arthritis.Inflammation · 2022Article
- Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function.iScience · 2021Article
- Diet, obesity, and the gut microbiome as determinants modulating metabolic outcomes in a non-human primate model.Microbiome · 2021Article
- Krill Oil Supplementation Reduces Exacerbated Hepatic Steatosis Induced by Thermoneutral Housing in Mice with Diet-Induced Obesity.Nutrients · 2021Article
- Gut-Derived Protein-Bound Uremic Toxins.Toxins · 2020Review
- Development of a sensitive and quantitative method for the identification of two major furan fatty acids in human plasma.Journal of lipid research · 2020Article
- Serum 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid is associated with lipid profiles and might protect against non-alcoholic fatty liver disease in Chinese individuals.Journal of diabetes investigation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Prescription ω-3 fatty acid ethyl ester supplements are commonly used for the treatment of hypertriglyceridemia. However, the metabolic profile and effect of the metabolites formed by these treatments remain unknown. Here we utilized unbiased metabolomics to identify 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) as a significant metabolite of the ω-3-acid ethyl ester prescription Lovaza™ in humans. Administration of CMPF to mice before or after high-fat diet feeding at exposures equivalent to those observed in humans increased whole-body lipid metabolism, improved insulin sensitivity, increased beta-oxidation, reduced lipogenic gene expression, and ameliorated steatosis. Mechanistically, we find that CMPF acutely inhibits ACC activity, and induces long-term loss of SREBP1c and ACC1/2 expression. This corresponds to an induction of FGF21, which is required for long-term steatosis protection, as FGF21KO mice are refractory to the improved metabolic effects. Thus, CMPF treatment in mice parallels the effects of human Lovaza™ supplementation, revealing that CMPF may contribute to the improved metabolic effects observed with ω-3 fatty acid prescriptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.